Stock listing
NYSE American:NSRX Nasus Pharma Ltd. Stock
Home listing (NYSE American) of Nasus Pharma Ltd.
Follow Nasus Pharma Ltd. into a list and get an email when it puts out news.
Share price · AMEX:NSRX
$2.29 USD -0.41 (-15.2%)
Close on Nov 20, 2026
- Day range
- $2.20 – $2.59 USDNov 20, 2026
- Volume
- 33,961 sharesNov 20, 2026
- Market cap
- $26.82M USDAt the close on Nov 20, 2026 · price × 11.71M shares outstanding
- 52-week range
- $1.98 – $9.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $58,852 USDMedian day 13,416 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:NSRX · Home | $2.29 USD | -0.41 (-15.2%) | 33,961 | $2.50 | $2.59 | $2.20 | $2.70 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:NSRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.29 | -0.41 | -15.2% | $2.50 | $2.59 | $2.20 | 33,961 | |
| $2.70 | +0.09 | +3.4% | $2.70 | $2.74 | $2.68 | 11,659 | |
| $2.61 | -0.05 | -1.9% | $2.59 | $2.61 | $2.541 | 4,959 | |
| $2.66 | -0.21 | -7.3% | $2.75 | $2.855 | $2.51 | 25,494 | |
| $2.87 | +0.05 | +1.8% | $2.935 | $2.935 | $2.81 | 4,675 | |
| $2.82 | -0.09 | -3.1% | $2.90 | $2.914 | $2.76 | 8,554 | |
| $2.91 | -0.075 | -2.5% | $2.90 | $3.025 | $2.89 | 4,779 | |
| $2.985 | +0.05 | +1.7% | $2.939 | $2.985 | $2.86 | 13,764 | |
| $2.935 | +0.115 | +4.1% | $2.763 | $2.96 | $2.763 | 17,555 | |
| $2.82 | -0.09 | -3.1% | $2.82 | $3.01 | $2.78 | 6,990 | |
| $2.91 | -0.01 | -0.3% | $2.865 | $3.015 | $2.75 | 34,665 | |
| $2.92 | -0.28 | -8.8% | $3.25 | $3.36 | $2.91 | 26,352 | |
| $3.20 | +0.001 | 0.0% | $3.31 | $3.395 | $3.10 | 15,734 | |
| $3.199 | +0.129 | +4.2% | $3.10 | $3.32 | $3.10 | 4,749 | |
| $3.07 | -0.12 | -3.8% | $3.23 | $3.27 | $3.07 | 4,888 | |
| $3.19 | -0.15 | -4.5% | $3.34 | $3.40 | $3.19 | 10,574 | |
| $3.34 | +0.02 | +0.6% | $3.39 | $3.40 | $3.19 | 5,384 | |
| $3.32 | -0.17 | -4.9% | $3.285 | $3.50 | $3.285 | 10,981 | |
| $3.49 | 0.00 | 0.0% | $3.41 | $3.607 | $3.41 | 15,034 | |
| $3.49 | +0.26 | +8.0% | $3.20 | $3.585 | $3.09 | 35,236 | |
| $3.23 | +0.17 | +5.6% | $3.31 | $3.61 | $3.12 | 33,361 | |
| $3.06 | -0.18 | -5.6% | $3.20 | $3.63 | $3.03 | 44,422 | |
| $3.24 | +0.035 | +1.1% | $3.21 | $3.33 | $3.21 | 19,851 | |
| $3.205 | +0.025 | +0.8% | $3.13 | $3.39 | $3.09 | 19,076 | |
| $3.18 | +0.015 | +0.5% | $3.09 | $3.24 | $3.09 | 15,042 | |
| $3.165 | -0.015 | -0.5% | $3.22 | $3.22 | $3.05 | 6,515 | |
| $3.18 | +0.02 | +0.6% | $3.23 | $3.31 | $3.08 | 13,342 | |
| $3.16 | -0.16 | -4.8% | $3.22 | $3.33 | $3.10 | 13,416 | |
| $3.32 | -0.19 | -5.4% | $3.33 | $3.44 | $3.242 | 30,876 | |
| $3.51 | -0.12 | -3.3% | $3.63 | $3.661 | $3.44 | 16,920 | |
| $3.63 | -0.145 | -3.8% | $3.78 | $3.78 | $3.50 | 14,033 | |
| $3.775 | -0.065 | -1.7% | $3.855 | $3.91 | $3.757 | 9,572 | |
| $3.84 | -0.01 | -0.3% | $3.88 | $3.913 | $3.77 | 17,224 | |
| $3.85 | -0.07 | -1.8% | $4.00 | $4.03 | $3.80 | 9,569 | |
| $3.92 | +0.105 | +2.8% | $3.82 | $4.10 | $3.79 | 28,711 | |
| $3.815 | +0.125 | +3.4% | $4.00 | $4.007 | $3.76 | 28,616 | |
| $3.69 | +0.12 | +3.4% | $4.00 | $4.00 | $3.60 | 57,383 | |
| $3.57 | -0.02 | -0.6% | $3.76 | $3.79 | $3.538 | 37,356 | |
| $3.59 | +0.11 | +3.2% | $3.69 | $3.78 | $3.35 | 115,666 | |
| $3.48 | 0.00 | 0.0% | $3.50 | $3.595 | $3.425 | 20,955 | |
| $3.48 | -0.16 | -4.4% | $3.35 | $3.50 | $3.35 | 3,940 | |
| $3.64 | +0.07 | +2.0% | $3.57 | $3.79 | $3.50 | 14,915 | |
| $3.57 | +0.13 | +3.8% | $3.48 | $3.68 | $3.45 | 12,454 | |
| $3.44 | -0.09 | -2.5% | $3.46 | $3.53 | $3.35 | 6,426 | |
| $3.53 | 0.00 | 0.0% | $3.35 | $3.58 | $3.35 | 12,021 | |
| $3.53 | +0.07 | +2.0% | $3.535 | $3.586 | $3.46 | 7,639 | |
| $3.46 | -0.13 | -3.6% | $3.64 | $3.72 | $3.41 | 10,949 | |
| $3.59 | -0.06 | -1.6% | $3.62 | $3.767 | $3.45 | 18,441 | |
| $3.65 | +0.245 | +7.2% | $3.262 | $3.80 | $3.262 | 21,174 | |
| $3.405 | +0.055 | +1.6% | $3.498 | $3.50 | $3.405 | 4,210 | |
| $3.35 | -0.20 | -5.6% | $3.16 | $3.477 | $3.16 | 10,715 | |
| $3.55 | -0.33 | -8.5% | $3.47 | $3.565 | $3.17 | 4,443 | |
| $3.88 | +0.145 | +3.9% | $3.53 | $3.973 | $3.47 | 8,676 | |
| $3.735 | -0.015 | -0.4% | $3.53 | $3.735 | $3.53 | 829 | |
| $3.75 | -0.02 | -0.5% | $3.515 | $3.765 | $3.23 | 15,098 | |
| $3.77 | -0.055 | -1.4% | $4.037 | $4.037 | $3.68 | 1,894 | |
| $3.825 | -0.259 | -6.3% | $3.85 | $4.08 | $3.43 | 15,677 | |
| $4.084 | -0.016 | -0.4% | $3.902 | $4.10 | $3.87 | 4,658 | |
| $4.10 | 0.00 | 0.0% | $3.985 | $4.10 | $3.984 | 14,574 | |
| $4.10 | +0.05 | +1.2% | $4.05 | $4.10 | $4.05 | 8,827 | |
| $4.05 | -0.05 | -1.2% | $4.09 | $4.09 | $3.869 | 4,463 | |
| $4.10 | +0.03 | +0.7% | $4.08 | $4.10 | $3.99 | 10,210 | |
| $4.07 | +0.07 | +1.8% | $3.98 | $4.07 | $3.765 | 17,392 | |
| $4.00 | +0.15 | +3.9% | $3.805 | $4.00 | $3.655 | 29,900 | |
| $3.85 | +0.01 | +0.3% | $3.665 | $3.85 | $3.51 | 11,200 |
- Ticker
- NYSE American:NSRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 44 slides
Latest news
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
Nov 16, 2026
Closed $2.66 (-7.3%) on Nov 16, 2026
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Sep 14, 2026
Closed $3.65 (+7.2%) on Sep 14, 2026
Nasus Pharma Announces Transition of Chief Financial Officer
Aug 19, 2026
Closed $3.84 (+5.2%) on Aug 19, 2026
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Aug 17, 2026
Closed $3.70 (+2.2%) on Aug 17, 2026
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Jul 28, 2026
Closed $3.03 (-1.9%) on Jul 28, 2026
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Jun 9, 2026
Closed $2.90 (-0.3%) on Jun 9, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Mar 25, 2026
Closed $2.76 (+10.8%) on Mar 25, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
Mar 16, 2026
Closed $3.10 (-38.0%) on Mar 16, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Mar 9, 2026
Closed $4.11 (-15.4%) on Mar 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Mar 9, 2026
Closed $4.11 (-15.4%) on Mar 9, 2026
Nasus Pharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 24 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 11 decks · latest July 2026
Where Nasus Pharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:NSRX · Home listing · This page | NYSE American | United States | USD |
| BOATS:NSRX | BOATS | United States | USD |
Valuation
Price/book 2.4× against a median of 1.9×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $15.11M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.99
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nasus Pharma Ltd. · AMEX:NSRX | US$26.82M | US$15.11M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.99 |
| Holy Stone Healthcare Co., Ltd. · TPEX:4194 | US$27.49M | US$25.08M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| SoftOx Solutions AS · OSL:SOFTX | US$27.28M | US$25.25M | n/a | n/a | n/a | 11.6× | n/a | 0.0× | n/a |
| Edesa Biotech, Inc. · NASDAQ:EDSA | US$27.02M | US$16.72M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.47 |
| Amplia Therapeutics Ltd. · ASX:ATX | US$26.84M | US$8.63M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Telomir Pharmaceuticals, Inc. · NASDAQ:TELO | US$26.82M | US$22.30M | n/a | n/a | n/a | 6.1× | n/a | 0.0× | 1.74 |
| Aprogen, Inc · KRX:007460 | US$26.80M | US$21.45M | n/a | 0.2× | n/a | 0.6× | −60.1% | 0.6× | n/a |
| BriaCell Therapeutics Corp · TSX:BCT | US$26.79M | US$6.25M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.07 |
| Alterity Therapeutics Ltd. · ASX:ATH | US$26.76M | US$2.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| EyePoint, Inc. · NASDAQ:EYPT | US$26.65M | −US$72.44M | n/a | −28.1× | n/a | 0.3× | n/a | 0.2× | 1.36 |
| PolTREG Spolka Akcyjna · GPW:PTG | US$26.08M | US$22.35M | n/a | 378× | n/a | 2.2× | n/a | 0.1× | n/a |
| Median of the others | US$26.81M | US$19.08M | 0.2× | 1.9× | −60.1% | 0.0× | 1.22 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.13 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brendan O’Grady | Chief Executive Officer, Board Member |
| Eyal Rubin | Executive Vice President and Chief Financial Officer |
| Nir Sassi | Chief Financial Officer |
| Dalia Megiddo | Co-founder, Board Member, Chief Development Officer |
| Udi Gilboa | Executive Chairman |
Board
| Director | Role |
|---|---|
| Udi Gilboa | Executive Chairman |
| Brendan O’Grady | Chief Executive Officer, Board Member |
| Dalia Megiddo | Co-founder, Board Member, Chief Development Officer |
| David Silberman | Board Member |
| Isaac Israel | Board Member |
| Ronnie Hershman | Board Member |
| Sharon Shacham | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Feb 25, 2026 | −3.0% |
| Q3 2025 | Dec 3, 2025 | −6.5% |
| Q2 2025 | Sep 3, 2025 | −0.4% |
| Q4 2024 | Mar 21, 2025 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 44 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 44 slides | Jun 9, 2026 |
| Investor Presentation (March 2026) | Investor deck | 44 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 67 slides | Feb 26, 2026 |
| Investor Presentation (January 2026) | Investor deck | 48 slides | January 2026 |
| Investor Presentation (December 2025) | Investor deck | 31 slides | December 2025 |
| Investor Presentation (November 2025) | Investor deck | 31 slides | November 2025 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | November 2025 |
| Investor Presentation (October 2025) | Investor deck | 30 slides | October 2025 |
| Investor Presentation (August 2025) | Investor deck | 26 slides | August 2025 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (July 2025) | IPO roadshow | 29 slides | Jul 30, 2025 |
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares and accompanying warrants Closed: US$15M raised · US$5.565 a share · 1 warrant at US$6.53 for 24 months · Citizens Capital Markets +1 Dealers: Citizens Capital Markets (lead), Laidlaw & Company (UK) Ltd. Insiders: Certain members of the Company's Board of Directors are participating Use of proceeds: Advance pivotal clinical development of NS002 for anaphylaxis, start first-in-human studies for other pipeline products, working capital and general purposes | Feb 13, 2026 |
| Public offering of ordinary shares Closed: US$10M raised · US$8 a share · Laidlaw & Company (UK) Ltd. +1 Dealers: Laidlaw & Company (UK) Ltd. (co-lead), Craft Capital Management LLC (co-lead) Use of proceeds: Development of intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies; general corporate purposes and working capital | Aug 14, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$8.00 a share on Aug 12, 2025.
- Price
- US$8.00 a share
- Shares offered
- 1,250,000 ordinary shares
- Offering size
- US$10 million
- Listing
- NSRX on NYSE American
- Underwriters
- Laidlaw & Company (UK) Ltd., CRAFT CAPITAL MANAGEMENT LLC · In the order on the cover
- Shares delivered
- On or about Aug 14, 2025
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 30, 2024 |
| Filed publicly | Jul 9, 2025 |
| Amended twice | Newest Aug 7, 2025 |
| Shares registered with an exchange | Aug 8, 2025 |
| Declared effective by the SEC | Aug 12, 2025 |
| Final prospectus, with the price | Aug 14, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 14, 2025 |
| EFFECT · Notice that a registration is effective | Aug 12, 2025 |
| CERT · Exchange's certificate of listing | Aug 12, 2025 |
| CORRESP · Letter to the SEC | Aug 8, 2025 |
| CORRESP · Letter to the SEC | Aug 8, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 8, 2025 |
| CORRESP · Letter to the SEC | Aug 7, 2025 |
| F-1/A · Registration statement, amended | Aug 7, 2025 |
| UPLOAD · Letter from the SEC | Aug 6, 2025 |
| FWP · Free writing prospectus | Jul 30, 2025 |
All 37 filings
Open IPO · From the cover of the final prospectus (424B4) filed Aug 14, 2025
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 1.24B | 0 | 0 | 0 |
| Research and development | 2.24M | 335.0K | 567.0K | 1.12M |
| Selling, general and administrative | 2.67M | 743.0K | 580.0K | 926.0K |
| Operating income | -4.90M | -1.08M | -1.15M | -2.04M |
| Interest expense | -78.0K | 29.0K | 49.0K | 18.0K |
| Income before tax | -5.80M | -1.55M | -1.00M | -2.15M |
| Net income | -5.86M | -1.53M | -1.05M | -1.71M |
| Earnings per share, basic | -0.72 | -0.22 | -0.15 | -0.19 |
| Earnings per share, diluted | -0.72 | -0.22 | -0.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 1.24M | 284.0K | 193.0K | 154.0K |
| Short-term investments | 3.05M | 0 | ||
| Current assets | 4.86M | 457.0K | 444.0K | 417.0K |
| Property, plant and equipment | 14.0K | |||
| Total assets | 5.00M | 717.0K | 444.0K | 417.0K |
| Accounts payable | 829.0K | 651.0K | 655.0K | 771.0K |
| Current liabilities | 2.16M | 3.93M | 4.24M | 3.20M |
| Total debt | 118.0K | 1.80M | 2.46M | 1.57M |
| Total liabilities | 2.24M | 3.93M | 4.24M | 3.20M |
| Shareholders' equity | 2.77M | -3.21M | -3.80M | -2.79M |
| Shares outstanding | 9.02M | 7.36M | 9.02M | 9.06M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -4.92M | -665.0K | -1.03M | -1.21M |
| Capital spending | -14.0K | 0 | 0 | 0 |
| Free cash flow | -4.93M | -665.0K | -1.03M | -1.21M |
| Cash from investing | -3.01M | -160.0K | ||
| Cash from financing | 8.92M | 770.0K | 1.05M | 1.24M |
| Change in cash | 980.0K | 101.0K | 39.0K | -143.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 19, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 8, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 21, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Sep 18, 2026 | Offer document | SEC |
All 105 filings
Cap table
Built by 6ix from Nasus Pharma Ltd.’s releases · as of Feb 13, 2026
- Common shares
- 11,713,808
- Fully diluted
- 14,409,226
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 11,713,808 | |
| Warrants | 2,695,418 | Feb 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$6.53 · expire about Feb 2028 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,713,808 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brendan O’Grady Other companies: Assertio Holdings, Inc. (CEO, Director · Since at least May 29, 2024); Teva Pharmaceutical Industries Limited (EVP, North America Commercial · Jan 1, 2018 – Mar 4, 2021 · Past) | Chief Executive Officer, Director · Since at least Jul 27, 2026 |
| David Silberman Other companies: Compugen Ltd. (Chief Financial Officer · Since at least Mar 18, 2026); Oramed Pharmaceuticals Inc. (Chief Financial Officer · Jul 5, 2021 – Jan 4, 2024 · Past) | Board Member · Since at least Mar 18, 2026 |
| Eyal Rubin Other companies: Protalix BioTherapeutics, Inc. (de) (Sr. VP and CFO · Sep 22, 2019 – Sep 23, 2024 · Past); Brainstorm Cell Therapeutics Inc. (CFO and Treasurer · Nov 20, 2017 – Nov 20, 2017 · Past) | Executive Vice President and Chief Financial Officer · Since at least Nov 20, 2025 |
| Sharon Shacham Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); Karyopharm Therapeutics Inc. (Chief Scientific Officer · Sep 16, 2019 – Mar 29, 2022 · Past) | Board Member · Since at least Mar 18, 2026 |
| Oren Elmaliah Other companies: MySize, Inc. (CHIEF FINANCIAL OFFICER · Since at least May 1, 2017) | Interim CFO · Since at least Sep 19, 2026 |
| Dalia Megiddo | Co-founder, Board Member, Chief Development Officer · Since at least Nov 17, 2026 |
| Isaac Israel | Board Member · Since at least Nov 4, 2026 |
| Nir Sassi | Chief Financial Officer · Since Nov 11, 2026 |
| Ronnie Hershman | Director · Since at least Mar 18, 2026 |
| Ronnie Hershman | Board Member · Since at least Nov 4, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Udi Gilboa | Executive Chairman · Since at least Aug 19, 2026 |
Log in to ask 6ix AI your own questions about Nasus Pharma Ltd.